One of the first reports of PD-1/PD-L1 inhibition in breast cancer was a phase 1b trial of the anti-PD-1 antibody pembrolizumab in 32 women with PD-L1-“positive” metastatic triple negative breast cancer (mTNBC) (KEYNOTE-012) [7]. The gene discussed is CD274; the disease is breast carcinoma.